Free tool
Rare disease stocks
We cover 5 companies grouped under the Rare disease theme. The median market value in the group is $16.85M. Across the group, the median move over the past trading day is +9.43%. Price change over the past year runs from −69.8% to +5281.0% across the middle 80 percent of the group, with a median of −25.6%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
5 of 268 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| NSRX | Nasus Pharma Ltd. | $48.01M | Micro cap | −49.75% |
| VYNE | VYNE Therapeutics Inc | $19.07M | Micro cap | +8660.74% |
| CMMB | Chemomab Therapeutics Ltd. | $16.85M | Micro cap | −25.57% |
| AZTR | Azitra, Inc. | $10.48M | Micro cap | −83.21% |
| GLMD | Galmed Pharmaceuticals Ltd. | $4.48M | Micro cap | +211.51% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.